Tolerability

Azilect^® (rasagiline) is well tolerated with a placebo-like side-effect profile. The most common adverse events with Azilect^® (rasagiline) treatment are shown in Table 1.

Adverse events occurring with an incidence of >5% in the Azilect® (rasagiline) 1 mg/day group and with a frequency of >2% over placebo (ref.1)

• Parkinson's disease is associated with symptoms of hallucinations and confusion. In post marketing experience these symptoms have also been observed in Parkinson's disease patients treated with Azilect^® (rasagiline). Please see prescribing_information
• Low discontinuation rates due to adverse events - comparable to placebo in monotherapy (ref.2) and adjunct treatment trials (ref.3, ref.4)
• Equally well tolerated in younger and elderly patients(>70 years) (ref.4)

Please see Summary of Product Characteristics for full prescribing information.

References:

1. Prescribing Information

2. Safety of rasagiline in elderly patients with Parkinson disease

Goetz CG. et al., Neurology 2006; 66(9):1427-9

3. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations: a randomised, double-blind, parallel-group trial - The LARGO study

Rascol O. et al. for the LARGO study Group, Lancet 2005; 365:947-954

4. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study

Parkinson Study Group, Arch Neurol 2005; 62:241-248

5. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. The TEMPO study (12-month data)

Parkinson Study Group, Arch Neurol 2004; 61:561-566

6. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study (6-month data)

Parkinson Study Group, Arch Neurol 2002; 59:1937-1943

7. Long-Term Efficacy of Rasagiline in Early Parkinson's

Lew MF. et al., Int J Neurosci 2010; 120:404-408

8. A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease

Olanow CW. et al., N Engl J Med 2010; 362:657-659
Published: 15/03/2006   Last updated: 10/05/2011